Pricing Log in Create free account

DiaMedica Therapeutics, Inc. (DMAC) vs Indaptus Therapeutics, Inc. (INDP)

DiaMedica Therapeutics, Inc. and Indaptus Therapeutics, Inc. are both Biotechnology companies. DiaMedica Therapeutics, Inc. and Indaptus Therapeutics, Inc. are of similar size ($437.7M and $433.6M). Across the 8 metrics below, DiaMedica Therapeutics, Inc. leads on 4 and Indaptus Therapeutics, Inc. on 4.

Valuation

Metric DMAC INDP Biotechnology median
P/E n/m n/m 8.50
P/S n/m n/m 9.71
P/B 10.68 26.86 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m n/m 9.21
Earnings yield (9.47%) (240.51%) (33.15%)
Free cash flow yield (7.70%) (4.81%) (25.50%)

Profitability

Metric DMAC INDP Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (114.62%) (318.04%) (56.36%)
Return on assets (98.18%) (163.84%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric DMAC INDP Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) (16.67%) 52.15% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DMAC INDP Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.72 19.48 4.72
Net debt to EBITDA 1.70 0.43 0.96

Dividend

Metric DMAC INDP Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric DMAC INDP Biotechnology median
Market cap 433.56m 437.70m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack